Search for information about a product,
therapeutic area or event

Media, investors, advocacy organizations and others, please contact us here.

Posters FSGS

Newly Administered Immunosuppressive Therapy (IST) Has No Impact on Long-term Antiproteinuric Effect of Sparsentan (SPAR), a Dual Angiotensin and Endothelin Receptor Antagonist, in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS): Interim Analysis of the Phase 2 DUET Trial

Posters FSGS

Long-term Effects of Sparsentan, a Dual Angiotensin and Endothelin Receptor Antagonist in Primary Focal Segmental Glomerulosclerosis (FSGS): Interim 84-Week Analysis of the DUET Trial

Posters FSGS

Antiproteinuric Effect of Sparsentan, A Dual Angiotensin II and Endothelin Type A Receptor Antagonist, in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS): A Subgroup Analysis of the DUET Trial

Posters FSGS

Long-Term Effect of Sparsentan (SPAR), a Dual Angiotensin and Endothelin Receptor Antagonist, on Proteinuria in Patients with Primary FSGS: Interim Analysis of the DUET Trial